Gene · 6195
Papers3,575
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 3,575
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Involvement of the AKT Pathway in Resistance to Erlotinib and Cabozantinib in Triple-Negative Breast Cancer Cell Lines. | Biomedicines | 2023 | 37760847 | PubTator, text mining | PubMed |
| Differentiating Benign from Malignant Thyroid Tumors by Kinase Activity Profiling and Dabrafenib BRAF V600E Targeting. | Cancers (Basel) | 2023 | 37760447 | PubTator, text mining | PubMed |
| Macrophages in the Inflammatory Phase following Myocardial Infarction: Role of Exogenous Ubiquitin. | Biology (Basel) | 2023 | 37759657 | PubTator, text mining | PubMed |
| Fragment merging approach for design, synthesis, and biological assessment of urea/acetyl hydrazide clubbed thienopyrimidine derivatives as GSK-3β inhibitors. | BMC Chem | 2023 | 37759329 | PubTator, text mining | PubMed |
| Structural biology of complement receptors. | Front Immunol | 2023 | 37753090 | PubTator, text mining | PubMed |
| Hydrogen peroxide-dependent oxidation of ERK2 within its D-recruitment site alters its substrate selection. | iScience | 2023 | 37744034 | PubTator, text mining | PubMed |
| Synergistic effects of flavonoids and paclitaxel in cancer treatment: a systematic review. | Cancer Cell Int | 2023 | 37743502 | PubTator, text mining | PubMed |
| Emerging proteins involved in castration‑resistant prostate cancer via the AR‑dependent and AR‑independent pathways (Review). | Int J Oncol | 2023 | 37732538 | PubTator, text mining | PubMed |
| Mapping the splicing landscape of the human immune system. | Front Immunol | 2023 | 37711610 | PubTator, text mining | PubMed |
| Continuous sensing of nutrients and growth factors by the mTORC1-TFEB axis. | Elife | 2023 | 37698461 | PubTator, text mining | PubMed |
| Angiotensin II modulates THP-1-like macrophage phenotype and inflammatory signatures via angiotensin II type 1 receptor. | Front Cardiovasc Med | 2023 | 37692050 | PubTator, text mining | PubMed |
| The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy. | Commun Biol | 2023 | 37684337 | PubTator, text mining | PubMed |
Lower magnitude and faster waning of antibody responses to SARS-CoV-2 vaccination in anti-TNF-α-treated IBD patients are linked to lack of activation and expansion of cTfh1 cells and impaired B memory cell formation. | EBioMedicine | 2023 | 37672867 | PubTator, text mining | PubMed |
| A new ferrocene derivative blocks K-Ras localization and function by oxidative modification at His95. | Life Sci Alliance | 2023 | 37666666 | PubTator, text mining | PubMed |
| Metabolic regulation of endothelial senescence. | Front Cardiovasc Med | 2023 | 37649668 | PubTator, text mining | PubMed |
| Protein Kinase C at the Crossroad of Mutations, Cancer, Targeted Therapy and Immune Response. | Biology (Basel) | 2023 | 37626933 | PubTator, text mining | PubMed |
| TUG1-mediated R-loop resolution at microsatellite loci as a prerequisite for cancer cell proliferation. | Nat Commun | 2023 | 37607907 | PubTator, text mining | PubMed |
| Yersinia pestis and Plague: some knowns and unknowns. | Zoonoses | 2023 | 37602146 | PubTator, text mining | PubMed |
| Breast cancer patient-derived microtumors resemble tumor heterogeneity and enable protein-based stratification and functional validation of individualized drug treatment. | J Exp Clin Cancer Res | 2023 | 37596623 | PubTator, text mining | PubMed |
| Resistance exercise: a mighty tool that adapts, destroys, rebuilds and modulates the molecular and structural environment of skeletal muscle. | Phys Act Nutr | 2023 | 37583075 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6195/papers?page=9